Close
What would you like to look for?
Site search
Search filters

Inositec AG acquired by Vifor Pharma

Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

RELIEF launches Level 1 ADR Program in the United States

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company, has launched its Level 1 American Depositary Receipt ("ADR") program in the United States. As of 18 November 2021, ADRs may be traded over the counter.

GlycoEra AG raises CHF 45m to Develop Novel Glycoengineering Platform

GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.

Claim against Swiss bank arising from fiduciary investments fended off

VISCHER successfully represented a Swiss bank in a multi-million dispute revolving around a fiduciary investment. The foreign bank had gone bankrupt.

MiniNaviDent AG enters into Cooperation with Straumann

MiniNaviDent has received an investment by Straumann Holding AG to further develop and market its DENACAM system, a miniaturized dynamic navigation system for dental implants. Furthermore, the company has simultaneously entered...

CRK joins the MYTY Group

The full-service PR and communications agency cR Kommunikation AG with offices in Bern, Basel and Zurich has joined the MYTY Group, a leading agency network in the DACH region.

Bachem raises CHF 583.5m to accelerate capacity expansion

Bachem Holding AG (SIX:BANB) has raised CHF 583.5m through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per share. Bachem is a leading, innovation-driven company specializing in...

Nautilus acquires Swiss motion tech company VAY, in Zurich

Nautilus, Inc., an innovation leader in home fitness, has acquired Zurich based VAY AG, a leader in motion detection and analysis.

A fund advised by AFINUM Management AG buys GS Swiss PCB

A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.

CombiGene and Spark enter global licensing agreement for gene therapy

STOCKHOLM - CombiGene AB and Spark Therapeutics announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project.

You are currently offline. Some pages or content may fail to load.